These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15692997)

  • 21. Pharmacogenetics in the rheumatic diseases, from prêt-à-porter to haute couture.
    Cronstein BN
    Nat Clin Pract Rheumatol; 2006 Jan; 2(1):2-3. PubMed ID: 16932642
    [No Abstract]   [Full Text] [Related]  

  • 22. An update on methotrexate.
    Braun J; Rau R
    Curr Opin Rheumatol; 2009 May; 21(3):216-23. PubMed ID: 19373092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methotrexate induced lymphoma?
    Bleyer WA
    J Rheumatol; 1998 Mar; 25(3):404-7. PubMed ID: 9517755
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases.
    Stamp LK; Roberts RL
    Pharmacogenomics; 2011 Oct; 12(10):1449-63. PubMed ID: 22008049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Trends in the treatment of rheumatic diseases].
    Trotta F; Padovan M
    Recenti Prog Med; 1999 Oct; 90(10):510-4. PubMed ID: 10592735
    [No Abstract]   [Full Text] [Related]  

  • 26. S100 proteins in rheumatic diseases.
    Austermann J; Spiekermann C; Roth J
    Nat Rev Rheumatol; 2018 Sep; 14(9):528-541. PubMed ID: 30076385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Tolerance of anti-TNF alpha: the experience acquired in inflammatory rheumatic disease].
    Mariette X
    Ann Dermatol Venereol; 2006 May; 133(5 Pt 2):1S8-12. PubMed ID: 16967603
    [No Abstract]   [Full Text] [Related]  

  • 28. Medical treatment of adolescents with rheumatic disease.
    Hollister JR
    Adolesc Med; 1998 Feb; 9(1):163-70, vii. PubMed ID: 10961259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs.
    Ledingham J; Gullick N; Irving K; Gorodkin R; Aris M; Burke J; Gordon P; Christidis D; Galloway S; Hayes E; Jeffries A; Mercer S; Mooney J; van Leuven S; Galloway J;
    Rheumatology (Oxford); 2017 Jun; 56(6):865-868. PubMed ID: 28339817
    [No Abstract]   [Full Text] [Related]  

  • 30. Overexpression of P-glycoprotein on fibroblast-like synoviocytes in refractory rheumatoid arthritis patients: a potential mechanism for multidrug resistance in rheumatoid arthritis treatment.
    Liu YM; Chen JW; Chen LX; Xie X; Mao N
    Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Reducing toxicity of methotrexate with folic acid].
    Harten P
    Z Rheumatol; 2005 Jun; 64(5):353-8. PubMed ID: 15965822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Introduction.
    Cantini F
    Expert Opin Drug Saf; 2016 Dec; 15(sup1):1. PubMed ID: 27924647
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacoepidemiology and rheumatic disorders.
    Chan KA; Hernandez-Diaz S
    Rheum Dis Clin North Am; 2004 Nov; 30(4):835-50, vii. PubMed ID: 15488696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Caveats to the use of parenteral methotrexate in the treatment of rheumatic disease.
    Moitra RK; Ledingham JM; Hull RG; McCrae FC; Thomas AL; Shaban R; Mackay KR
    Rheumatology (Oxford); 2005 Feb; 44(2):256-7. PubMed ID: 15637036
    [No Abstract]   [Full Text] [Related]  

  • 35. [Fetal safety profile of drugs used in the treatment of inflammatory rheumatic diseases].
    Falcão S; Mourão AF; Pimentão JB; Branco JC
    Acta Reumatol Port; 2007; 32(4):323-31. PubMed ID: 18159198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel immunological targets in rheumatic diseases: clues from current therapies.
    D'Acquisto F; Rattazzi L; Piras G; Galuppo ML
    Drug Discov Today; 2014 Aug; 19(8):1155-60. PubMed ID: 24984284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Magnetic resonance imaging in rheumatologic practice: low field or standard.
    Sharp JT
    J Rheumatol; 2006 Oct; 33(10):1925-7. PubMed ID: 17014009
    [No Abstract]   [Full Text] [Related]  

  • 38. [Hypertransaminemia and methotrexate: not always a toxic effect?].
    Montilla Morales C; López Longo FJ; Moreno Zazo M; Monteagudo Sáez I; Moreno García AC; Carreño Pérez L
    Rev Clin Esp; 1998 Dec; 198(12):822-4. PubMed ID: 9930004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The 2005 International Symposium on Advances in Targeted Therapies: what have we learned in the 2000s and where are we going?
    Maini RN
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4():iv106-8. PubMed ID: 16239377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study.
    Weber-Schoendorfer C; Chambers C; Wacker E; Beghin D; Bernard N; ; Shechtman S; Johnson D; Cuppers-Maarschalkerweerd B; Pistelli A; Clementi M; Winterfeld U; Eleftheriou G; Pupco A; Kao K; Malm H; Elefant E; Koren G; Vial T; Ornoy A; Meister R; Schaefer C
    Arthritis Rheumatol; 2014 May; 66(5):1101-10. PubMed ID: 24470106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.